Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 Inhibikase Therapeutics, Inc. , a.
Inhibikase Therapeutics (IKT) Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing.